An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

NCT07018570 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions

DRUG: Pembrolizumab
DRUG: Docetaxel
DRUG: Oxaliplatin
DRUG: Levofolinate
DRUG: Fluorouracil (5-FU)
RADIATION: Radiation Therapy

Sponsor

National Cancer Center Hospital East

Collaborators

[object Object]